parsaclisib (INCB50465) / Incyte 
Welcome,         Profile    Billing    Logout  
 3 Diseases   27 Trials   27 Trials   276 News 


12345678»
  • ||||||||||  parsaclisib (INCB50465) / Incyte, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
    P1 data, Journal, Combination therapy:  Safety and efficacy of parsaclisib in combination with rituximab, bendamustine?+?rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL?112). (Pubmed Central) -  Apr 10, 2024   
    P1
    The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62.5%, 50.0%, and 50.0% of patients in Treatments A, B, and C, respectively); diarrhea (37.5%) and anemia (31.3%) in Treatment A; abdominal pain, asthenia, diarrhea, and nausea (each 33.3%) in Treatment B; and increased alanine and aspartate aminotransferase (each 37.5%) in Treatment C. Objective responses were observed in 13 patients (81.3%) in Treatment A, 10 (55.6%) in Treatment B, and 8 (50.0%) in Treatment C. Parsaclisib combined with SOC therapies had an expected safety profile and promising efficacy in patients with R/R B-cell lymphomas.
  • ||||||||||  parsaclisib (INCB50465) / Incyte, gedatolisib (PF-05212384) / Celcuity, buparlisib (AN2025) / Novartis, Adlai Nortye
    Journal:  A Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer. (Pubmed Central) -  Mar 22, 2024   
    It is of inter-est with respect to efforts in the synthesis of a candidate anti-cancer drug, parsaclisib. The establishment of development indicators based on clinical trials for cancer treatment was useful to highlight the clinical investment in 3 new PI3K drugs and the advantages of combine therapy using FDA-approved drugs.
  • ||||||||||  parsaclisib (INCB50465) / Incyte
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov) -  Jul 3, 2023   
    P3,  N=13, Active, not recruiting, 
    Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Feb 2023 Recruiting --> Active, not recruiting | N=100 --> 13 | Trial completion date: Apr 2027 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2023
  • ||||||||||  Review, Journal:  Rise of the planet of rare anemias: An update on emerging treatment strategies. (Pubmed Central) -  Jan 27, 2023   
    PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan)...Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.